Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Gets Investor Advice On Transparency At White House Gathering

Executive Summary

FDA recently met with venture capitalists and drug industry leaders to discuss the agency's initiative to become more transparent. While such get-togethers are not unusual, the location of this one signaled how significant the topic is to FDA. Rather than meet at the agency's still-being-renovated headquarters in White Oak, participants gathered at the White House

You may also be interested in...



FDA Ponders Whether To Publicly Discuss Pending NDAs And INDs; Should Agency Reply To Studies Published In Journals?

FDA leadership is considering whether, and to what extent, the agency should be able to publicly discuss INDs, drug applications and complete response letters

FDA Ponders Whether To Publicly Discuss Pending NDAs And INDs; Should Agency Reply To Studies Published In Journals?

FDA leadership is considering whether, and to what extent, the agency should be able to publicly discuss INDs, drug applications and complete response letters

FDA Is Expanding Transparency Efforts To Focus On Industry Questions

Sharfstein said the agency has split up its transparency efforts into three groups, adding one dedicated to explaining its inner workings to regulated industry.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051405

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel